Alembic Pharma Doxycycline Hyclate Delayed-Release Tablets get USFDA okay
The approved Doxycycline Hyclate delayed release tablets are therapeutically equivalent to the reference listed drug product (RLD) Doryx Tablets, 75 mg, 100 mg, 150 mg, and 200 mg, of Mayne Pharma International Pty Ltd (Mayne).
New Delhi: Alembic Pharmaceuticals on Tuesday said it has received approval from the US health regulator to market Doxycycline Hyclate delayed-release tablets, used to treat drug resistant bacterial infections, in the American market.
The company has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Doxycycline Hyclate delayed-release tablets, the drug firm said in regulatory filing.
Also Read: USFDA approves Alembic Pharma Dabigatran Etexilate Capsules
The approved ANDA is therapeutically equivalent to the reference-listed drug product (RLD) Doryx Tablets, 75 mg, 100 mg, 150 mg, and 200 mg, of Mayne Pharma International Pty Ltd (Mayne).
Doxycycline Hyclate delayed-release tablets are indicated to reduce the development of drug resistant bacteria.
According to IQVIA data, Doxycycline Hyclate delayed-release tablets USP, 75 mg, 100 mg, 150 mg, and 200 mg have an estimated market size of USD 10 million for twelve months ending September 2021.
Also Read: Alembic Pharma gets USFDA nod for pulmonary arterial hypertension drug Selexipag
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.